Neighborhood disadvantage, or living in a poorer region, was linked to significantly shorter survival time for ALS patients ...

A mishap with her ankle-foot orthoses was discouraging, but columnist Dagmar Munn quickly happened upon the "mini-miracles" that followed.

A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

After more than a decade of living with her husband's ALS, columnist Kristin Neva has found the equipment to be helpful in ...

Repeated brain injury resulted in SOD1-ALS mice showing greater weight loss, an earlier tremor in the hind limbs, and ...

Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

Qure is planning soon to start enrolling patients in a second dose group as part of a clinical trial testing AMT-162 for SOD1 ...

Neuropeutics is collaborating with LifeArc on a small molecule therapy that reportedly lowered TDP-43 clumping in an animal ...

Masitinib is an oral inhibitor of tyrosine kinases, enzymes important for immune cells thought to drive ALS inflammation and ...